COCH
Envoy Medical, Inc.
There isn't enough reported data to score COCH yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
COCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Strong |
COCH's balance sheet is currently strong, and its revenue is stable, but its profitability is weak. There isn't enough data to rate its cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
COCH PE Valuation
COCH has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
COCH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect COCH's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
COCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | +$10.20 |
| Q2 2026 | -$7.70 | +$7.40 |
| Q1 2026 | -$10.20 | +$4.40 |
| Q4 2025 | -$12.30 | +$2.60 |
COCH has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
COCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $66K | +57% |
| Q2 2026 | $51K | -35% |
| Q1 2026 | $39K | -15% |
| Q4 2025 | $75K | +79% |
| Q3 2025 | $42K | -25% |
| Q2 2025 | $78K | +15% |
| Q1 2025 | $46K | -22% |
| Q4 2024 | $42K | -56% |
COCH's revenue is recovering but still below its 2023 peak: $66,000 last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8389% | +5201 points |
| Q2 2026 | -10920% | -4420 points |
| Q1 2026 | -15279% | -4177 points |
| Q4 2025 | -8513% | +2258 points |
| Q3 2025 | -13590% | -4708 points |
| Q2 2025 | -6500% | +647 points |
| Q1 2025 | -11102% | -2801 points |
| Q4 2024 | -10771% | -3682 points |
COCH's operating margin was −8389% last quarter, up 5201 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over COCH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over COCH on profitability, with a higher operating margin.
COCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.1M | -$726K |
| Q4 2025 | -$5.9M | -$2M |
| Q3 2025 | -$4.3M | -$367K |
| Q4 2024 | -$3.9M | +$7.9M |
COCH has burned cash in almost every quarter: −$20M over the past year, against −$23M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
COCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +30.6K shares |
| 1 year | +378% | +8.2M shares |
| 3 years | +96% | +5.1M shares |
COCH has 10M diluted shares, up 378% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over COCH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
COCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -0.0x | Net Cash |
| Q3 2021 | -0.1x | Net Cash |
COCH has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
COCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 62.7 | Neutral |
COCH's weekly RSI is 49 (neutral) and its Stochastic is 63 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
COCH PE vs Healthcare Sector
| Metric | COCH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
COCH has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
COCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.72 | 1.3% above |
| 20 week MA | $6.96 | 2.2% below |
| 50 week MA | $6.90 | 1.3% below |
| 100 week MA | $10.1 | 33% below |
| 200 week MA | $32.4 | 79% below |
COCH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
COCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $97.5 | $97.4 | -0.1% |
| 2022 | $97.4 | $99.7 | +2.4% |
| 2023 | $99.7 | $18.1 | -82% |
| 2024 | $18.1 | $16.0 | -12% |
| 2025 | $16.0 | $7.30 | -54% |
| 2026 YTD | $7.30 | $6.81 | -6.7% |
COCH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.